SCHEMBL14825129

SCHEMBL14825129

Cc1sc(NC(=O)CCc2ccccc2)c(C(=O)O)c1C

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.64
HTT P42858 3/20 0.64
SMN1; SMN2 Q16637 3/20 0.64
RECQL P46063 1/20 0.64
MAPT P10636 5/20 0.60
HPGD P15428 4/20 0.55
LMNA P02545 3/20 0.55
NPSR1 Q6W5P4 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
POLB P06746 2/20 0.52
CNR2 P34972 1/20 0.52
AIP O00170 1/20 0.51
SGTA O43765 1/20 0.51
TOMM70 O94826 1/20 0.51
STIP1 P31948 1/20 0.51
PPP5C P53041 1/20 0.51
FKBP4 Q02790 1/20 0.51
PPID Q08752 1/20 0.51
FKBP5 Q13451 1/20 0.51
FKBP8 Q14318 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13781560 0.92 ALDH1A1 (0.56) ALDH1A1HTTSMN1; SMN2RECQLMAPT
SCHEMBL13781600 0.87 HCAR2 (0.56) ALDH1A1HTTSMN1; SMN2RECQLMAPT
SCHEMBL23413257 0.76 ALDH1A1 (0.83) ALDH1A1HTTSMN1; SMN2MAPTHPGD
SCHEMBL14825388 0.74 FLT3 (0.79) ALDH1A1HTTSMN1; SMN2MAPTHPGD
SCHEMBL1800640 0.73 ALDH1A1 (0.72) ALDH1A1HTTSMN1; SMN2MAPTHPGD
SCHEMBL1954227 0.73 TSHR (0.45) ALDH1A1HTTSMN1; SMN2MAPTHPGD
SCHEMBL13781563 0.72 HCAR2 (0.52) SMN1; SMN2POLBCNR2NPC1RAB9A
SCHEMBL31541275 0.71 ALDH1A1 (1.00) ALDH1A1HTTSMN1; SMN2MAPTHPGD
SCHEMBL7003055 0.71 AIP (0.74) ALDH1A1HTTSMN1; SMN2RECQLMAPT
SCHEMBL21612947 0.71 ALDH1A1 (0.61) ALDH1A1HTTMAPTHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130085133-A1 ANTI-VIRAL TREATMENT AND ASSAY TO SCREENFOR ANTI-VIRAL AGENT Sourthern Research Institute Office of Commercialization and Intellectual Prop. (US) 2013-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130085133-A1 ANTI-VIRAL TREATMENT AND ASSAY TO SCREENFOR ANTI-VIRAL AGENT MAVS, SNRPE, LONP1 ALDH1A1 3082/4885HTT 4221/4885SMN1; SMN2 1270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.